Asosiy kontentga oʻtish
Maqola

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

Ronald BoellaardDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands, [email protected]Roberto C. Delgado BoltonDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), University of La Rioja, Logroño, SpainWim J.G. OyenDepartment of Nuclear Medicine, Centre Hospitalier Universitaire de Lyon, Lyon, FranceFrancesco GiammarileDepartment of Nuclear Medicine, Centre Hospitalier Universitaire de Lyon, Lyon, FranceKlaus TatschDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsW. EschnerDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsFred VerzijlbergenDepartment of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands,Sally F. BarringtonAmsterdam UMC Location Vrije Universiteit AmsterdamLucy PikeDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsWolfgang WeberDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsSigrid StroobantsDepartment of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USADominique DelbekeBeth Israel Deaconess Medical Center, Boston, MA, USAKevin DonohoeDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsScott HolbrookDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsMichael M. GrahamDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsGiorgio TestaneraDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsOtto S. HoekstraDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsJosée M. ZijlstraDepartment of Nuclear Medicine, Jeroen Bosch Hospital, Den Bosch, The NetherlandsEric P. VisserAmsterdam UMC Location Vrije Universiteit AmsterdamC. HoekstraDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsJan PruimDepartment of Nuclear Medicine & Molecular Imaging, University Medical Centre Groningen, Groningen, The NetherlandsAntoon T. M. WillemsenDepartment of Nuclear Medicine & Molecular Imaging, University Medical Centre Groningen, Groningen, The NetherlandsBertjan ArendsJ. Kotzerke Clinic and Outpatient Clinic for Nuclear Medicine, University Hospital Dresden, Dresden, GermanyJörg KotzerkeDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsAndreas BockischClinic for Nuclear Medicine, University Hospital Essen, Essen, GermanyThomas BeyerCentre for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AustriaArturo ChitiDepartment of Radiology & Nuclear Medicine, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsBernd J. KrauseDepartment of Nuclear Medicine, University Hospital Rostock, Rostock, Germany
2014en
ABI

Annotatsiya

The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique and therefore requires a common quality control (QC)/quality assurance (QA) procedure to maintain the accuracy and precision of quantitation. Repeatability and reproducibility are two essential requirements for any quantitative measurement and/or imaging biomarker. Repeatability relates to the uncertainty in obtaining the same result in the same patient when he or she is examined more than once on the same system. However, imaging biomarkers should also have adequate reproducibility, i.e. the ability to yield the same result in the same patient when that patient is examined on different systems and at different imaging sites. Adequate repeatability and reproducibility are essential for the clinical management of patients and the use of FDG PET/CT within multicentre trials. A common standardised imaging procedure will help promote the appropriate use of FDG PET/CT imaging and increase the value of publications and, therefore, their contribution to evidence-based medicine. Moreover, consistency in numerical values between platforms and institutes that acquire the data will potentially enhance the role of semiquantitative and quantitative image interpretation. Precision and accuracy are additionally important as FDG PET/CT is used to evaluate tumour response as well as for diagnosis, prognosis and staging. Therefore both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

3 ta iqtibos0 ta foydalanilgan manba